39736-28-2Relevant articles and documents
NOVEL BICYCLIC HETEROCYCLIC COMPOUND
-
Paragraph 0475; 0476, (2018/09/27)
Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
Lin, Ronghui,Johnson, Sigmond G.,Connolly, Peter J.,Wetter, Steven K.,Binnun, Eva,Hughes, Terry V.,Murray, William V.,Pandey, Niranjan B.,Moreno-Mazza, Sandra J.,Adams, Mary,Fuentes-Pesquera, Angel R.,Middleton, Steven A.
scheme or table, p. 2333 - 2337 (2009/12/07)
2,7-Diamino-thiazolo[4,5-d]pyrimidine analogues were synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds showed potent and selective EGFR inhibitory activities and inhibited in vitro cellular p
THIAZOLOPYRIMIDINE KINASE INHIBITORS
-
Page/Page column 49-50, (2008/06/13)
The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof, and the use thereof as inhibitors of ATP-protein kinase interactions.